Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy

被引:14
作者
Jiang, Qi [1 ]
Zeng, Xiangyu [1 ]
Zhang, Chenggang [1 ]
Yang, Ming [2 ]
Fan, Jun [2 ]
Mao, Gan [1 ]
Shen, Qian [1 ]
Yin, Yuping [1 ]
Liu, Weizhen [1 ]
Tao, Kaixiong [1 ]
Zhang, Peng [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, Wuhan 430022, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pathol, Wuhan 430022, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
Lymph node ratio; Gastric cancer; Neoadjuvant chemotherapy; Tumor regression grade; PERIOPERATIVE CHEMOTHERAPY; NUTRITIONAL INDEX; D2; GASTRECTOMY; ADENOCARCINOMA; CAPECITABINE; OXALIPLATIN; REGRESSION; SURVIVAL; RESOLVE; S-1;
D O I
10.1186/s12957-022-02725-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The accuracy of lymph node ratio (LNR) as a prognostic index remains to be proven for gastric cancer patients after neoadjuvant chemotherapy (NACT). This study sought to investigate the prognostic value of LNR in locally advanced gastric cancer (LAGC) patients after NACT. Methods LAGC patients with clinical TNM stages 2-3, Her2(-), and Eastern Cooperative Oncology Group, scores 0-2 are routinely scheduled with NACT. Patients with LAGC after NACT and surgical operation between January 2012 and October 2020 were retrospectively reviewed. The correlation between LNR and survival was investigated. Results Overall, 148 patients were enrolled: 103 with low-LNR (LNR <= 30%) and 45 with high-LNR (LNR > 30%). Approximately, 50.5% and 24.4% patients responded to NACT at the primary site in the low-LNR and high-LNR groups, respectively. The overall survival (OS) and progression-free survival (PFS) of low-LNR group were considerably better than those of high-LNR group (3-year OS: 81.9% vs 18.5%, P < 0.001; 3-year PFS: 72.6% vs 13.5%, P < 0.001). In the low-LNR group, OS and PFS were superior in patients with tumor regression grade (TRG) 0-2 than in those with TRG 3 (3-year OS: 89.2% vs 73.2%, P = 0.086; 3-year PFS: 80.3% vs 66.5%, P = 0.036). In association with OS and PFS, the degree of tumor differentiation, TRG, and LNR were identified as predictive factors, and LNR was identified as the independent prognostic factor in univariate and multivariate analyses, respectively. Conclusions LNR is a prospective index of prognosis in patients with LAGC after NACT.
引用
收藏
页数:10
相关论文
共 34 条
  • [11] After neoadjuvant chemotherapy platelet/lymphocyte ratios negatively correlate with prognosis in gastric cancer patients
    Gong, Weipeng
    Zhao, Lei
    Dong, Zhaogang
    Dou, Yu
    Liu, Yanguo
    Ma, Chao
    Qu, Xun
    [J]. JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2018, 32 (05)
  • [12] Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial
    Grenader, T.
    Waddell, T.
    Peckitt, C.
    Oates, J.
    Starling, N.
    Cunningham, D.
    Bridgewater, J.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (04) : 687 - 692
  • [13] Modified Gastric Cancer AJCC Staging with a Classification Based on the Ratio of Regional Lymph Node Involvement: A Population-Based Cohort Study
    Huang, Zeping
    Chen, Yutong
    Zhang, Wenjun
    Liu, Haipeng
    Wang, Zixian
    Zhang, Youcheng
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (05) : 1480 - 1487
  • [14] Jaffer AA, 2020, GASTRIC CANC VERSION
  • [15] Japanese gastric cancer treatment guidelines 2014 (ver. 4)
    Japanese Gastric Cancer Association
    [J]. GASTRIC CANCER, 2017, 20 (01) : 1 - 19
  • [16] Ji J, 2019, ANN ONCOL, V30, P877
  • [17] High Systemic Immune-Inflammation Index is an Adverse Prognostic Factor for Patients With Gastroesophageal Adenocarcinoma
    Jomrich, Gerd
    Paireder, Matthias
    Kristo, Ivan
    Baierl, Andreas
    Ilhan-Mutlu, Ayseguel
    Preusser, Matthias
    Asari, Reza
    Schoppmann, Sebastian F.
    [J]. ANNALS OF SURGERY, 2021, 273 (03) : 532 - 541
  • [18] Kakar S., 2017, AJCC CANC STAGING MA
  • [19] Kang YK, 2019, ANN ONCOL, V30, P876
  • [20] The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy
    Li, Ziyu
    Li, Shuangxi
    Ying, Xiangji
    Zhang, Lianhai
    Shan, Fei
    Jia, Yongning
    Ji, Jiafu
    [J]. GASTRIC CANCER, 2020, 23 (03) : 540 - 549